vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Astera Labs, Inc. (ALAB). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($308.4M vs $268.1M, roughly 1.2× ACADIA PHARMACEUTICALS INC). Astera Labs, Inc. runs the higher net margin — 26.0% vs 1.4%, a 24.7% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (93.4% vs 9.7%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (100.3% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
ACAD vs ALAB — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $308.4M |
| Net Profit | $3.6M | $80.3M |
| Gross Margin | — | 76.3% |
| Operating Margin | -1.7% | 20.1% |
| Net Margin | 1.4% | 26.0% |
| Revenue YoY | 9.7% | 93.4% |
| Net Profit YoY | — | 152.4% |
| EPS (diluted) | $0.02 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $308.4M | ||
| Q4 25 | $284.0M | $270.6M | ||
| Q3 25 | $278.6M | $230.6M | ||
| Q2 25 | $264.6M | $191.9M | ||
| Q1 25 | $244.3M | $159.4M | ||
| Q4 24 | $259.6M | $141.1M | ||
| Q3 24 | $250.4M | $113.1M | ||
| Q2 24 | $242.0M | $76.8M |
| Q1 26 | $3.6M | $80.3M | ||
| Q4 25 | $273.6M | $45.0M | ||
| Q3 25 | $71.8M | $91.1M | ||
| Q2 25 | $26.7M | $51.2M | ||
| Q1 25 | $19.0M | $31.8M | ||
| Q4 24 | $143.7M | $24.7M | ||
| Q3 24 | $32.8M | $-7.6M | ||
| Q2 24 | $33.4M | $-7.5M |
| Q1 26 | — | 76.3% | ||
| Q4 25 | 90.8% | 75.6% | ||
| Q3 25 | 92.2% | 76.2% | ||
| Q2 25 | 92.2% | 75.8% | ||
| Q1 25 | 91.7% | 74.9% | ||
| Q4 24 | 91.6% | 74.0% | ||
| Q3 24 | 92.5% | 77.7% | ||
| Q2 24 | 92.5% | 77.9% |
| Q1 26 | -1.7% | 20.1% | ||
| Q4 25 | 6.1% | 24.7% | ||
| Q3 25 | 12.8% | 24.0% | ||
| Q2 25 | 12.2% | 20.7% | ||
| Q1 25 | 7.9% | 7.1% | ||
| Q4 24 | 59.1% | 0.1% | ||
| Q3 24 | 12.6% | -7.9% | ||
| Q2 24 | 12.6% | -31.7% |
| Q1 26 | 1.4% | 26.0% | ||
| Q4 25 | 96.3% | 16.6% | ||
| Q3 25 | 25.8% | 39.5% | ||
| Q2 25 | 10.1% | 26.7% | ||
| Q1 25 | 7.8% | 20.0% | ||
| Q4 24 | 55.4% | 17.5% | ||
| Q3 24 | 13.1% | -6.7% | ||
| Q2 24 | 13.8% | -9.8% |
| Q1 26 | $0.02 | $0.44 | ||
| Q4 25 | $1.61 | $0.25 | ||
| Q3 25 | $0.42 | $0.50 | ||
| Q2 25 | $0.16 | $0.29 | ||
| Q1 25 | $0.11 | $0.18 | ||
| Q4 24 | $0.86 | $1.23 | ||
| Q3 24 | $0.20 | $-0.05 | ||
| Q2 24 | $0.20 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $148.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $148.3M | ||
| Q4 25 | $177.7M | $167.6M | ||
| Q3 25 | $258.0M | $140.4M | ||
| Q2 25 | $253.6M | $162.3M | ||
| Q1 25 | $217.7M | $86.4M | ||
| Q4 24 | $319.6M | $79.6M | ||
| Q3 24 | $155.1M | $126.1M | ||
| Q2 24 | $177.1M | $421.1M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $917.3M | $1.3B | ||
| Q2 25 | $822.4M | $1.1B | ||
| Q1 25 | $765.2M | $1.0B | ||
| Q4 24 | $732.8M | $964.8M | ||
| Q3 24 | $577.2M | $889.6M | ||
| Q2 24 | $516.7M | $845.3M |
| Q1 26 | $1.6B | $1.7B | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $976.9M | $983.1M | ||
| Q2 24 | $914.1M | $915.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $74.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $74.6M | ||
| Q4 25 | $-48.7M | $95.3M | ||
| Q3 25 | $74.3M | $78.2M | ||
| Q2 25 | $64.0M | $135.4M | ||
| Q1 25 | $20.3M | $10.5M | ||
| Q4 24 | $40.4M | $39.7M | ||
| Q3 24 | $63.2M | $63.5M | ||
| Q2 24 | $25.0M | $29.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $76.6M | ||
| Q3 25 | $73.9M | $65.9M | ||
| Q2 25 | — | $133.3M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | — | $24.3M | ||
| Q3 24 | $63.2M | $46.8M | ||
| Q2 24 | — | $28.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.3% | ||
| Q3 25 | 26.5% | 28.6% | ||
| Q2 25 | — | 69.5% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | 25.2% | 41.4% | ||
| Q2 24 | — | 37.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.9% | ||
| Q3 25 | 0.1% | 5.3% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | 0.0% | 14.8% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | 0.93× | ||
| Q4 25 | -0.18× | 2.12× | ||
| Q3 25 | 1.03× | 0.86× | ||
| Q2 25 | 2.40× | 2.64× | ||
| Q1 25 | 1.07× | 0.33× | ||
| Q4 24 | 0.28× | 1.61× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
